Alkermes plc. Current Liabilities
Alkermes plc. (ALKS) had Current Liabilities of $662.09 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-07-28
- 2026-06-30: Liabilities, Current $662.09M.
- 2026-03-31: Liabilities, Current $599.50M.
- 2025-12-31: Liabilities, Current $543.44M.
- 2025-09-30: Liabilities, Current $474.36M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $662.09M 10-Q · filed 2026-07-28 |
| 2026-03-31 | $599.50M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $543.44M 10-Q · filed 2026-07-28 |
| 2025-09-30 | $474.36M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $505.96M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $443.73M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $465.20M 10-K · filed 2026-02-25 |
| 2024-09-30 | $453.70M 10-Q · filed 2024-10-24 |
| 2024-06-30 | $515.55M 10-Q · filed 2024-07-24 |
| 2024-03-31 | $458.98M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $520.22M 10-K · filed 2025-02-12 |
| 2023-09-30 | $503.11M 10-Q · filed 2023-10-25 |
| 2023-06-30 | $487.19M 10-Q · filed 2023-07-26 |
| 2023-03-31 | $492.91M 10-Q · filed 2023-04-26 |
| 2022-12-31 | $497.74M 10-K · filed 2024-02-21 |
| 2022-09-30 | $469.56M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $438.52M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $462.36M 10-Q · filed 2022-04-27 |
| 2021-12-31 | $471.29M 10-K · filed 2023-02-16 |
| 2021-09-30 | $452.98M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $383.44M 10-Q · filed 2021-07-28 |
| 2021-03-31 | $365.84M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $438.26M 10-K · filed 2022-02-16 |
| 2020-09-30 | $378.15M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $321.41M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $339.85M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $391.11M 10-K · filed 2021-02-11 |
| 2019-09-30 | $370.39M 10-Q · filed 2019-10-23 |
| 2019-06-30 | $334.15M 10-Q · filed 2019-07-25 |
| 2019-03-31 | $327.69M 10-Q · filed 2019-04-25 |
| 2018-12-31 | $339.77M 10-K · filed 2020-02-13 |
| 2018-09-30 | $304.79M 10-Q · filed 2018-10-23 |
| 2018-06-30 | $287.47M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $274.53M 10-Q · filed 2018-04-26 |
| 2017-12-31 | $291.12M 10-K · filed 2019-02-15 |
| 2017-09-30 | $256.01M 10-Q · filed 2017-10-26 |
| 2017-06-30 | $224.64M 10-Q · filed 2017-07-27 |
| 2017-03-31 | $210.74M 10-Q · filed 2017-04-27 |
| 2016-12-31 | $211.99M 10-K · filed 2018-02-16 |
| 2016-09-30 | $190.24M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $236.26M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $224.13M 10-Q · filed 2016-04-28 |
| 2015-12-31 | $236.21M 10-K · filed 2017-02-17 |
| 2015-09-30 | $200.40M 10-Q · filed 2015-10-29 |
| 2015-06-30 | $134.22M 10-Q · filed 2015-07-30 |
| 2015-03-31 | $114.22M 10-Q · filed 2015-04-30 |
| 2014-12-31 | $130.58M 10-K · filed 2016-02-25 |
| 2014-09-30 | $110.14M 10-Q · filed 2014-10-29 |
| 2014-06-30 | $102.16M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $92.76M 10-Q · filed 2014-04-30 |
| 2013-12-31 | $100.90M 10-K · filed 2015-02-24 |
| 2013-09-30 | $73.72M 10-Q · filed 2013-10-31 |
| 2013-06-30 | $72.60M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $85.93M 10-KT · filed 2014-02-27 |
| 2012-12-31 | $77.28M 10-Q · filed 2013-01-31 |
| 2012-09-30 | $68.74M 10-Q · filed 2012-11-01 |
| 2012-06-30 | $71.24M 10-Q · filed 2012-07-26 |
| 2012-03-31 | $89.16M 10-K · filed 2013-05-23 |
| 2011-12-31 | $97.20M 10-Q · filed 2012-02-02 |
| 2011-09-30 | $90.32M 10-Q · filed 2011-11-03 |
| 2011-03-31 | $48.06M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |